Insider Transactions in Q1 2021 at Talis Biomedical Corp (TLIS)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 17
2021
|
Brian Coe Chief Executive Officer |
BUY
Conversion of derivative security
|
Indirect |
30,931
+29.56%
|
-
|
|
Feb 17
2021
|
Karen E. Flick Chief of Staff, Sr. VP, Legal |
BUY
Open market or private purchase
|
Direct |
2,000
+50.0%
|
$32,000
$16.0 P/Share
|
|
Feb 17
2021
|
Douglas Liu Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
4,000
+50.0%
|
$64,000
$16.0 P/Share
|
|
Feb 17
2021
|
John Roger Moody Jr Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
1,700
+50.0%
|
$27,200
$16.0 P/Share
|
|
Feb 17
2021
|
Matthew L. Posard Director |
BUY
Open market or private purchase
|
Direct |
62,500
+50.0%
|
$1,000,000
$16.0 P/Share
|
|
Feb 17
2021
|
Ramesh Ramakrishnan |
BUY
Open market or private purchase
|
Direct |
1,000
+50.0%
|
$16,000
$16.0 P/Share
|
|
Feb 17
2021
|
Randal W. Scott Director |
BUY
Open market or private purchase
|
Indirect |
312,500
+50.0%
|
$5,000,000
$16.0 P/Share
|
|
Feb 17
2021
|
Randal W. Scott Director |
BUY
Conversion of derivative security
|
Indirect |
1,390,064
+30.47%
|
-
|
|
Feb 17
2021
|
Kimberly J Popovits Director |
BUY
Conversion of derivative security
|
Indirect |
391,815
+44.36%
|
-
|
|
Feb 17
2021
|
Kimberly J Popovits Director |
BUY
Open market or private purchase
|
Indirect |
5,300
+2.4%
|
$84,800
$16.0 P/Share
|
|
Feb 17
2021
|
Kimberly J Popovits Director |
BUY
Conversion of derivative security
|
Direct |
22,041
+46.09%
|
-
|
|
Feb 17
2021
|
Baker Bros. Advisors LP Director |
BUY
Open market or private purchase
|
Indirect |
6,250,000
+44.86%
|
$100,000,000
$16.0 P/Share
|